L. Tran

Hepatocyte Targeting with Gd-EOB-DTPA: Potential Application for Gene Therapy

G. Frija, C. Cuénod, N. Siauve, 2001, Investigative radiology.

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

J. Baars, J. Beijnen, A. Huitema, 2009, Cancer biotherapy & radiopharmaceuticals.

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

J. Baars, J. Beijnen, A. Huitema, 2010, Human antibodies.

Preclinical characterisation of 111In‐DTPA‐trastuzumab

J. Bart, J. Kosterink, L. Tran, 2004, British journal of pharmacology.

MESOMARK: a potential test for malignant pleural mesothelioma.

N. Sardesai, H. Pass, W. J. Allard, 2007, Clinical chemistry.

47 4 PRECLINICAL CHARACTERIZATION OF 111 IN-DTPA-TRASTUZUMAB

J. Bart, J. Kosterink, L. Tran, 2005 .

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion

J. Baars, J. Beijnen, A. Huitema, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

J. Baars, J. Beijnen, A. Huitema, 2011, Human antibodies.

The preparation of radiolabeled monoclonal antibodies for human use.

J. Beijnen, A. Huitema, L. Tran, 2009, Human antibodies.

Three spectroscopic techniques evaluated as a tool to study the effects of iodination of monoclonal antibodies, exemplified by rituximab.

J. Baars, C. Damen, J. Beijnen, 2011, Journal of pharmaceutical and biomedical analysis.